🚨 #ESMO26 | Krascendo 1 (Phase 3) 🥇 First head-to-head KRAS G12C inhibitor trial 🥇 First KRAS G12C inhibitor to improve OS in NSCLC

Ahmed Alanazi | أحمد العنزي· @alanazi002 · X·2026-10-25 23:47· 1 天前评分70

正文 · 原文

🚨 #ESMO26 | Krascendo 1 (Phase 3) 🥇 First head-to-head KRAS G12C inhibitor trial 🥇 First KRAS G12C inhibitor to improve OS in NSCLC
Divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC (N=338) ✅ mOS 17.7 vs 12.0 mo (HR 0.56) ✅ mPFS 9.8 vs 5.7 mo (HR 0.58) ✅ ORR 58% vs 32%
@myESMO @OncoAlert

21 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Ahmed Alanazi | أحمد العنزي · x.com